Show simple item record

dc.contributor.authorYip, Agustín G.en_US
dc.contributor.authorGreen, Robert C.en_US
dc.contributor.authorHuyck, Matthewen_US
dc.contributor.authorCupples, L. Adrienneen_US
dc.contributor.authorFarrer, Lindsay A.en_US
dc.date.accessioned2011-12-29T21:00:03Z
dc.date.available2011-12-29T21:00:03Z
dc.date.copyright2005
dc.date.issued2005-1-12
dc.identifier.citationYip, Agustín G, Robert C Green, Matthew Huyck, L Adrienne Cupples, Lindsay A Farrer. "Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study." BMC Geriatrics5:2. (2005)
dc.identifier.issn1471-2318
dc.identifier.urihttps://hdl.handle.net/2144/2489
dc.description.abstractBACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAID) use may protect against Alzheimer's disease (AD) risk. We sought examine the association between NSAID use and risk of AD, and potential effect modification by APOE-ε4 carrier status and ethnicity. METHODS: The MIRAGE Study is a multi-center family study of genetic and environmental risk factors for AD. Subjects comprised 691 AD patients (probands) and 973 family members enrolled at 15 research centers between 1996 and 2002. The primary independent and dependent variables were prior NSAID use and AD case status, respectively. We stratified the dataset in order to evaluate whether the association between NSAID use and AD was similar in APOE-ε4 carriers and non-carriers. Ethnicity was similarly examined as an effect modifier. RESULTS: NSAID use was less frequent in cases compared to controls in the overall sample (adjusted OR = 0.64; 95% CI = 0.38–1.05). The benefit of NSAID use appeared more pronounced among APOE-ε4 carriers (adjusted OR = 0.49; 95% CI = 0.24–0.98) compared to non-carriers, although this association was not statistically significant. The pattern of association was similar in Caucasian and African Americans. CONCLUSIONS: NSAID use is inversely associated with AD and may be modified by APOE genotype. Prospective studies and clinical trials of sufficient power to detect effect modification by APOE-ε4 carrier status are needed.en_US
dc.language.isoen
dc.publisherBioMed Centralen_US
dc.rightsCopyright 2005 Yip et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution 2.0 License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/2.0
dc.titleNonsteroidal Anti-Inflammatory Drug Use and Alzheimer's Disease Risk: The MIRAGE Studyen_US
dc.typeArticleen_US
dc.identifier.doi10.1186/1471-2318-5-2
dc.identifier.pmid15647106
dc.identifier.pmcid546007


This item appears in the following Collection(s)

Show simple item record

Copyright 2005 Yip et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution 2.0 License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as Copyright 2005 Yip et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution 2.0 License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.